South Africa has welcomed a U.S. bridging plan worth $115 million to continue funding HIV treatment and prevention programs ...
South Africa's health minister has called lenacapavir, the first twice-yearly HIV prevention jab, a "groundbreaking" tool ...
In response, the South African National Treasury allocated R750 million in emergency funding to prevent service interruptions ...
Bizcommunity on MSN
Pepfar Bridge Plan gives South Africa's HIV/Aids efforts $115m boost
South Africa’s fight against HIV/Aids has received a boost with the USA government’s approval of the US President’s Emergency ...
The US has approved a US$115 million PEPFAR Bridge Plan to sustain South Africa’s HIV services from October 2025. Announced ...
Two Indian generic drugmakers — Hetero and Dr Reddy’s — will be funded by the Gates Foundation and Unitaid, respectively, to produce and sell the twice-a-year anti-HIV shot, lenacapavir, for $40 ...
A new HIV prevention drug will be made available at a lower cost in over 100 low-income countries within two years — a move expected to give millions access to the breakthrough treatment and ...
From 2027, Indian generics companies and Hetero Labs Dr. Reddy's will supply lenacapavir, a twice-yearly injectable PrEP with ~96-100% efficacy, for US$40 (R698) per person per year across 120 low- ...
Dr Reddy's, Hetero among six Indian companies with licensing deal from Gilead Sciences Global health groups like Unitaid, Gates working with generic manufacturers to lower prices, broaden access ...
Dr David Adetula is the Founder of Healthialogue and Convener of the Healthialogue Panel Session and Discussion Forum and Christian Okike is the President of the Medical Research and Humanitarian ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback